CB CAPS

Serial Number 85398286
602

Registration Progress

Application Filed
Aug 15, 2011
Under Examination
Approved for Publication
Published for Opposition
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: CB CAPS
Previous Owner: Exagen Diagnostics, Inc.
Classes: 042

Trademark Image

CB CAPS

Basic Information

Serial Number
85398286
Filing Date
August 15, 2011
Abandonment Date
June 13, 2012
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Jul 9, 2012
Classes
042

Rights Holder

Exagen Diagnostics, Inc.

03
Address
Suite 103
801 University Blvd. SE
Albuquerque, NM 87106

Ownership History

Exagen Diagnostics, Inc.

Original Applicant
03
Albuquerque, NM

Legal Representation

Attorney
David Harper

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

8 events
Date Code Type Description Documents
Jul 9, 2012 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Loading...
Jul 9, 2012 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Dec 12, 2011 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Dec 12, 2011 GNRT F NON-FINAL ACTION E-MAILED Loading...
Dec 12, 2011 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 6, 2011 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 18, 2011 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 18, 2011 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Medical and clinical chemical laboratory services used by medical professionals for systemic lupus erythematosus diagnosis, disease stratification, prognosis, therapy selection and therapy monitoring; medical laboratory services for detecting, providing prognosis and monitoring systemic lupus erythematosus disease in patients; medical laboratory services and clinical laboratory research in the field of early prediction algorithms that incorporate both clinical and laboratory parameters and assists in the monitoring, predicting and diagnosing of individuals who are likely to develop systemic lupus erythematosus
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
042